Physician profile
Robert S Rood
NPI 1033294731
$14,841.54
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $62.57.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,154.95 | 2019-2020 | |
| Novo Nordisk INC | $3,934.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $351.09 | 2019 | |
| Dexcom, INC. | $174.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.62 | 2019 | |
| Senseonics, Incorporated | $42.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.96 | 2019 | |
| Abbott Laboratories | $18.23 | 2019 | |
| Companion Medical, INC. | $17.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.